Longest survival follow-up ever reported for immunotherapy treatment in this setting
Submission based on results from pivotal phase III trial showing all primary endpoints met
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
Global Phase-3 study initiation expected in the second half of 2024
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The partners will collaborate to build a cutting-edge oligonucleotide cGMP manufacturing facility
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
